Research programme: leptin mimetics - AstraZeneca
Latest Information Update: 23 Dec 2009
At a glance
- Originator Cambridge Biotechnology
- Developer AstraZeneca
- Class Small molecules
- Mechanism of Action Leptin receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Obesity